Back to search results

Comparing Radiation Treatments for Laryngeal Cancer

This study is comparing two types of radiation treatment for laryngeal carcinoma (cancer of the voice box): LT-SABR and IMRT. LT-SABR uses fewer, higher doses of radiation, while IMRT uses more, smaller doses. The study aims to see which treatment causes fewer side effects in the first three months after treatment. You may be able to join if you are 18 or older, have a specific type of laryngeal cancer (squamous cell carcinoma or variants) that is stage 0-II, and meet other health criteria. The study plans to enroll 67 participants.

Study design
This is a randomized study, meaning participants will be assigned by chance to one of the two treatment groups. It plans to enroll 67 participants.
What's involved
You would have screening procedures within 30 days before starting, including a medical history, physical exam, imaging (PET/CT or CT neck), laryngoscopy, and quality of life questionnaires.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to measure side effects at 3 months following treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06080503

Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy

Recruiting
NAAges 18+InterventionalTreatment
University of Texas Southwestern Medical Center
~67 participants
Updated 2025-11-26 on ClinicalTrials.gov
What's tested:LT-SABRIMRT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To compare the acute toxicity outcomes between patients treated with highly-conformal hypofractionated radiotherapy and conventional radiotherapy.
Measured over 3 months following treatment

Conditions

Laryngeal Carcinoma

Explore related trials

Laryngeal Carcinoma

NCT06080503

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Texas Southwestern Medical Center

    Dallas, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • David Sher, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

David J Sher, MD,MPH
[email protected]
214-645-2465
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Has not undergone a hysterectomy or bilateral oophorectomy; or
Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 6. Ability to understand and the willingness to sign a written informed consent.

What this trial measures

  • To compare the acute toxicity outcomes between patients treated with highly-conformal hypofractionated radiotherapy and conventional radiotherapy.3 months following treatment

    Acute toxicity score (i.e. T score), defined as the mean number of grade 2 or higher acute toxicities experienced between the start of radiotherapy and 3 months following treatment.